Interplay Between Fibroblast Growth Factor-19, Beta-Klotho, and Receptors Impacts Cardiovascular Risk in Chronic Kidney Disease
Journal of Clinical Medicine · 27.01.2026 · 15 (3) · 1005
DOI: 10.3390/jcm15031005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.01.2026. Verfasst von Laura González-Rodríguez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Therapeutics, Medical School, Universidad de Extremadura, 06006 Badajoz, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Government of Extremadura, Extremadura Research Chair in Cardiovascular Risk Reduction.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) markedly increases the risk of cardiovascular events (CVE), yet conventional biomarkers often fail to capture this excess risk. We evaluated whether circulating levels and genetic variability within the FGF19/β-Klotho/FGFR axis contribute to CV risk stratification in CKD.
Methods
In 579 CKD patients, plasma FGF19 and β-Klotho concentrations were quantified, and 64 genetic variants across FGF19, KLB, FGFR1, and FGFR4 genes were analyzed.
Results
Cluster analysis identified three distinct biomarker profiles, with one cluster—characterized by low/intermediate FGF19 and markedly elevated β-Klotho—showing significantly reduced CV event-free survival. After adjustment for clinical covariates, this cluster was independently associated with higher CV risk [HR = 2.97 (1.12–7.92), p = 0.029]. Two genetic variants also showed independent associations: FGFR1 rs2288696 (protective) [HR = 0.51 (0.27–0.95), p = 0.029] and KLB rs2687971 (risk-increasing) [HR = 2.03 (0.97–4.27), p = 0.046]. A combined CV risk model incorporating biomarker clusters, relevant SNPs, and traditional risk factors achieved good discriminative ability (C-index = 0.80), with the FGF19/β-Klotho cluster showing predictive importance comparable to diabetes and previous CV history.
Conclusions
These results indicate that integrating FGF19-Klotho biomarkers with genetic information may improve CV risk prediction in CKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical and Surgical Therapeutics, Medical School, Universidad de Extremadura, 06006 Badajoz, Spain.
- RICORS2040 Renal Research Network, 28029 Madrid, Spain.
- Vascular and Renal Translational Research Group, Institute for Biomedical Research in Lleida, 25198 Lleida, Spain.
- Department of Medical and Surgical Therapeutics, Plasencia University Center, Universidad de Extremadura, 10600 Plasencia, Spain.
- Department of Biochemistry, Molecular Biology and Physiology, Universidad de Valladolid, 42004 Soria, Spain.
- GIR-Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoepidemiology, University of Valladolid, 47005 Valladolid, Spain.
ORCID-Profile: Laura González-Rodríguez, Manuel Martí-Antonio, Virginia Díaz-Acevedo, Sonia Mota-Zamorano, Celia Chicharro, Bárbara Cancho, Raquel Gil-Lozano, Zoraida Verde, Fernando Bandrés, Guillermo Gervasini
Förderung
- Instituto de Salud Carlos III
- Government of Extremadura
- Extremadura Research Chair in Cardiovascular Risk Reduction
- European Union
- European Regional Development Fund
- Regional Government of Extremadura
- Ministry of Finance
- Instituto de Salud Carlos III, Madrid
Zitieren
APA
González-Rodríguez, L., Martí-Antonio, M., Díaz-Acevedo, V., Mota-Zamorano, S., Chicharro, C., Cancho, B., Gil-Lozano, R., Verde, Z., Bandrés, F., Robles, N. R., & Gervasini, G. (2026). Interplay Between Fibroblast Growth Factor-19, Beta-Klotho, and Receptors Impacts Cardiovascular Risk in Chronic Kidney Disease. Journal of Clinical Medicine, 15(3), 1005. https://doi.org/10.3390/jcm15031005
Vancouver
González-Rodríguez L, Martí-Antonio M, Díaz-Acevedo V, Mota-Zamorano S, Chicharro C, Cancho B, et al. Interplay Between Fibroblast Growth Factor-19, Beta-Klotho, and Receptors Impacts Cardiovascular Risk in Chronic Kidney Disease. Journal of Clinical Medicine. 2026;15(3):1005. doi:10.3390/jcm15031005
BibTeX
@article{GonzlezRodrguez2026,
author = {González-Rodríguez, Laura and Martí-Antonio, Manuel and Díaz-Acevedo, Virginia and Mota-Zamorano, Sonia and Chicharro, Celia and Cancho, Bárbara and Gil-Lozano, Raquel and Verde, Zoraida and Bandrés, Fernando and Robles, Nicolás R and Gervasini, Guillermo},
title = {Interplay Between Fibroblast Growth Factor-19, Beta-Klotho, and Receptors Impacts Cardiovascular Risk in Chronic Kidney Disease},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {3},
pages = {1005},
doi = {10.3390/jcm15031005}
}
EUVIMED